Aegerion Pharmaceuticals Inc. (Nasdaq: AEGR) is buying Myalept, a medication, from AstraZeneca (NYSE: AZN) for $325 million.

Myalept is an injectable product that can be used for treatment in patients with lipodystrophy, which causes the loss of fat from under the skin. The lack of leptin, the cause of lipodystrophy, can lead to diabetes and other diseases. The product has approval from the U.S. Food & Drug Administration. The deal is expected to close in January.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.